We show here that analysis of VpreB gene transcription can be a specific way to identify acute leukemias of cells at very early stages of B-cell development. Northern blot analysis of RNAs from 63 leukemia samples showed that VpreB RNA was present in malignancies of precursor B cells, the expression being a feature of both common acute lymphoblastic leukemia (ALL) (CD10') and null ALL (CD10-). It was absent from malignancies of mature B cells (surface lg positive), from acute leukemias of the T-cell lineage and granulocytemacrophage lineages, and from normal tonsil B and T lympho-HE CELLULAR ORIGIN of most acute leukemias T can be determined by using a combination of morphologic, histochemical, and cell surface marker analysis.' These determinations usually require use of several markers because most markers are not fully stage and/or lineage specific. A potential lineage-and stage-specific marker for human precursor B cells, the VpreB gene, was recently identified' after description of mouse pre-B-cell-specific genes AS, VpreB,, and VpreB,." In both human and mouse, the VpreB gene is expressed in pre-B-cell lines but not in mature B-, T-, or myeloid-lineage cell lines. It shares structural features and much sequence identity with Ig light chain variable region genes. The human and mouse homologs of the VpreB gene share 80% sequence identity, including a carboxyl-terminal portion of 27 to 30 amino acids that are not homologous to Ig genes or to any other reported gene sequences. Rearrangement is not required for VpreB gene expression.2.6 The human VpreB gene is located on the long arm of chromosome 22 within band 22q11.2, very near or within the IgLA-chain locus.' In human pre-B-cell lines, the 18-Kd protein product of the VpreB gene can be found in a complex containing the Ig p chain and protein of the A, gene."' Likewise, the mouse VpreB and A5 proteins can assemble in an Ig-like complex with the p heavy chain in both transfected cell lines'*^'' and mouse pre-B-cell lines.14 l6 These features suggest that the VpreB gene plays an important role in early B-cell differentiation and might serve as a useful tool for characterization and diagnosis of early B-cell neoplasms. Herein, we have studied the expression of the VpreB gene at the RNA level in a panel of 63 leukemias and found that expression of VpreB gene RNA can indeed be used as a stage-and lineage-specific marker for early B-lymphoid leukemic cells.
T can be determined by using a combination of morphologic, histochemical, and cell surface marker analysis.' These determinations usually require use of several markers because most markers are not fully stage and/or lineage specific. A potential lineage-and stage-specific marker for human precursor B cells, the VpreB gene, was recently identified' after description of mouse pre-B-cell-specific genes AS, VpreB,, and VpreB,." In both human and mouse, the VpreB gene is expressed in pre-B-cell lines but not in mature B-, T-, or myeloid-lineage cell lines. It shares structural features and much sequence identity with Ig light chain variable region genes. The human and mouse homologs of the VpreB gene share 80% sequence identity, including a carboxyl-terminal portion of 27 to 30 amino acids that are not homologous to Ig genes or to any other reported gene sequences. Rearrangement is not required for VpreB gene expression.2.6 The human VpreB gene is located on the long arm of chromosome 22 within band 22q11.2, very near or within the IgLA-chain locus.' In human pre-B-cell lines, the 18-Kd protein product of the VpreB gene can be found in a complex containing the Ig p chain and protein of the A, gene."' Likewise, the mouse VpreB and A5 proteins can assemble in an Ig-like complex with the p heavy chain in both transfected cell lines'*^'' and mouse pre-B-cell lines.14 l6 These features suggest that the VpreB gene plays an important role in early B-cell differentiation and might serve as a useful tool for characterization and diagnosis of early B-cell neoplasms. Herein, we have studied the expression of the VpreB gene at the RNA level in a panel of 63 leukemias and found that expression of VpreB gene RNA can indeed be used as a stage-and lineage-specific marker for early B-lymphoid leukemic cells.
MATERIALS AND METHODS
Northern blot ana(ysis. For experiment 1, total RNA was prepared as described by Chirgwin et al." For experiments 2 and 3, RNA was prepared as described by Chomczynski et a1.I' Frozen leukemic samples were obtained from banks maintained at Birmingham, AL and Birmingham, UK. Total RNA samples were electrophoresed through 1.1% agarose gels in l x MOPS buffer, transferred to nylon filters (Hybond-N; Amersham, UK), and fixed to the filters by UV irradiation. Both prehybridization and hybridization were performed at 42°C for 16 hours in a mixture containing 5X SSPE, 50% formamide, SX Denhardt's solution, 100 pg/mL salmon sperm DNA, 100 pgimL yeast tRNA, 2 mmoliL EDTA, and 0.1% sodium dodecyl sulfate (SDS) ( I x Denhardt's = 0.02% cytes. Chronic myeloid leukemia blast crises of the B-precursor-cell type expressed the VpreB gene while myeloid blast crises did not. VpreB RNA was also expressed in the neoplastic cells of one of three patients with acute undifferentiated leukemias. These data show that VpreB RNA expression is a marker of the malignant forms of precursor B cells, and that it appears at least as early as cytoplasmic CD22 and CD19 in tumors of the B-cell lineage. 0 1991 by The American Society of Hematology.
bovine serum albumin, 0.02% polyvinylpyrolidone, 0.02% Ficoll; l x SSPE = 150 mmoliL NaC1, 10 mmol/L NaH,PO,, 1 mmoliL EDTA, pH = 7.4). Washing of filters after hybridization was first performed three times for 20 minutes in 2 x SSPE, 0.1% SDS, 1 mmoliL EDTA at 22"C, then in 0.1X SSPE, 0.1% SDS, 1 mmoliL EDTA at 65°C three times for 20 minutes. The VpreB probe was a 250-bp BamHI-Bgl I fragment from the 3' untranslated region of the human VpreB gene clone pHWB-6.2 The p-actin probe was a 1.5-kb Pst I fragment from cDNA clone PAL 41.19 Probes were labeled with "P by random (oligonucleotide) primer labeling?' Hybridization reactions contained 3 x lo6 CPMimL of probe (Cerenkow counting). Cell surface marker phenotypes were determined as described below and were shown after the Northern blot analysis in experiments 2 and 3 was completed.
For samples from the University of Birmingham, UK (UK samples), lineage assignment of acute leukemias was determined on morphologic grounds with the following supportive phenotypic analysis: B-lineage acute lymphoblastic leukemias (ALLs) other than L3 were defined as being surface (s) CD19+, cytoplasmic (c) CD22+, sMHC class II', nuclear (n) TdT', sIg-, and sCD7-. These leukemias were classified as null ALL when sCD10-or as common ALL (CALL). The CALL group was subdivided into cp', ck-, and cp?, with the last group comprising those patients with CALL for whom testing for cytoplasmic p was not performed. One patient with L3 ALL had neoplastic cells that were sCD19', sIgM', sIgD', sCD10+, and sCD38+. Another patient with centroblastic lymphoma with associated leukemia had cells with similar cell marker expression. The diagnosis in these cases was based on the distinct cytology of the two neoplasms and the clinical features of the patient's disease. T-lineage ALL (TALL) was defined as being sCD7', nTdT+, and s and/or cCD3'.
Sample designation.
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Further distinctions among T A L L are not reported here because T A L L RNAs did not hybridize to the VpreB probe. Acute myeloid leukemias (AMLs) were subclassified using the FrenchAmerican-British (FAD) system with additional evidence provided by myeloperoxidase activity. sCD13, sCD33, and sCD14 expression. Acute undifierentiated leukemias (AULs) were defined as being sCD34' but cCD3'. sCD I T , sCD13-, sCD33-and myeloperoxidase negative.
For 
RESULTS
Human lcukcmic samples wcrc analyzed for thc prcscncc of VprcB RNA in thrcc scparatc Northern blot cxpcriments. Thc first cxpcrimcnt, shown in Fig I, analyted lcukcmic samples of prc-B, mature B, T, and mycloid lincagcs. T and B lymphocytcs from normal tonsil wcrc also studicd. RNA from two prc-B-ccll lincs (697 and 207) hybridized with the VprcB probc, consistent with our prcvious findings.' Thrcc prc-B-ALL samples cxpressed the 850-bp VprcB RNA. In contrast, a mycloid blast crisis of chronic myeloid lcukemia (CML), four mature B-ccll Icukcmias, onc T-cell leukcmia, thrcc myeloid-cell Icukcmias, and normal tonsillar T or B lymphocytcs did not cxprcss VpreB RNA (Fig 1) .
Thcsc observations suggcstcd that thc cxprcssion of thc VprcB gene may bc rcstrictcd to precursor B-cell Icukcmias. To test this idca in a less biased way and with a larger number of samplcs, wc pcrformcd two additional cxpcriments (Figs 2 and 3) in which RNA was prcparcd from numbcrcd samplcs whosc phcnotypc was shown only aftcr thc Northern blot analysis was complctcd.
In thc second cxpcrimcnt (Fig 2) , very small amounts of RNA were obtaincd from some of thc frozen leukcmia cell samples. Hybridization with an actin probc was used to compare thc quantities of RNA analyzed for each samplc.
Various amounts of total RNA from thc prc-B-ccll line Nalm 16 wcrc cxamincd to dctcrminc thc sensitivity of dctcction for both VprcB and actin probes. Both thc actin and VprcB signals wcrc visible and proportional to thc amount of RNA in thc rangc of 1 to 10 pg. Among thc lcukcmia samples, six of thc cight prccursor B-lcukcmic RNA samples (null ALL, cALL cp-, and cALL cp-) contained dctcctablc VprcB and actin RNA. Myeloid-and T-lincagc lcukcmias did not express VprcB RNA. Two of thrcc CML blast crises wcrc of thc B-progcnitor-ccll type and contained VprcB RNA, whilc a third CML blast crisis of thc mycloid type did not. Onc of two AULs was positive for VprcB RNA. Howcvcr, as shown by the intensity of hybridization with the actin probe, thc VpreB-ncgativc AUL contained approximatcly 10-fold less RNA than the VprcB-positive AUL. Thc low amount of RNA may have prccludcd detection of VprcB RNA in this samplc.
In Therefore, for these samples, all of the RNA was loaded rather than sacrificing some to quantify the amount of RNA. Northern blot analysis and sequential hybridization with the VpreB and p-actin probes were performed as described in Materials and Methods. The autoradiograms were exposed as described in Fig  1 for 3 days [VpreB probe) and 2 days (actin probe). After Northern blot analysis was complete, the samples were identified according to the clinical designation and labeled accordingly on this blot. For simplicity, the precursor Bcell leukemias [null ALL5 and the CALLS) are all labeled as pre-B-ALL in Figs 2 and 3. Table  1 lists the leukemia samples in the order that they appear from left t o right across the top of the Northern blot panels. Total RNAs from human pre-&ell lines Nalm 6 and Nalm 16 were included as controls for VpreB hybridization. The bottom panel includes a titration of Nalm 16 RNAfrom 1 to 10 pg to estimate the sensitivity of this screening procedure. of thc RNA after clcctrophorcsis showcd that RNA from one prc-B-ALL was dcgradcd (Fig 3) . RNA was quantified by measurement of the optical absorbance at 260 nm. Five micrograms of RNA was loaded on the gel and analyzed with the VpreB probe in Northern blots as described above. Before transfer of the electrophoresed RNA, the gel was stained with ethidium bromide and photographed. MW indicates the lanes containing molecular weight standards. Ethidium bromide staining patterns showed that equivalent amounts of intact RNA were analyzed for most samples and that pre-EALLsample 2367 (bottom hybridization panel, left-most lane) had been degraded before analysis. RNA from human pre-&ell line Nalm 16 was used as a positive control for VpreB hybridization. The autoradiogram was exposed for 7 days as described in Fig 1 . Table  1 lists the leukemia samples in the order that they appear from left t o right across the top of the Northern blot panels.
types such as AULs because one of three AUL samples expressed VprcB RNA.
Northern blot analysis of VprcB RNA expression can consistently identify acute leukemia cells in which maturational arrest was judged to have occurred at the B-cell precursor stage by conventional phenotypic analysis involving morphologic, histochemical, and immunologic mcthods. The diagnosis of the malignancies was pcrformcd in two different institutions by slightly diffcrcnt mcthods; howcvcr, the idcntification of precursor R-ALLs was consistently DISCUSSION Prc-B-ccll leukemias were originally identified by their cytoplasmic expression of chains," but this feature docs not pcrmit the idcntification of all precursor B-cell malignancics. ' In thc present cxpcrimcnts, we have shown that 
Correspondence to Northern Blot data in Figs 1 through 3 . With the exception of the positive control RNAs (cell lines 207,697, Nalm 6 and Nalm 16) the samples in this table are listed in the order in which they appear from left to right across the top of the Northern blot panel designated by figure number under sample ID. UAB samples are designated by patient initials, UK samples are designated by sample numbers. Samples were diagnosed and are designated as described in Materials and Methods. The lg isotype expressed by the mature B-cell malignancies is shown in parentheses. In the VpreB RNA column, (+)denotes hybridization with the VpreB probe, (?) denotes a sample with degraded RNA and therefore inconclusive result, and (-) denotes no hybridization with the VpreB probe. Note that AUL sample 2257 was inadvertantly included two times, once in experiment 2 and once in experiment 3.
*The parentheses were included to show a designation that coincides with the UK sample designation.
accomplished using the VpreB probe for both sets of samples.
The results of the present experiments extend and agree with our earlier observation that the VpreB gene is transcribed in pre-B-cell lines but not in mature B-cell lines or cell lines from other lineages in cells of both mice and humans.2s6 Among the samples of malignant cells, 95% of the precursor B-cell malignancies expressed VpreB RNA, while normal or malignant mature B cells or cells from other lineages did not.
The lineage fidelity of VpreB gene expression found in the present study mirrors that of other markers that are expressed in precursors of hematopoietic cell lineages.
These other markers include myeloperoxidase in the precursors of granulocytes and macrophagesz,26; cytoplasmic CD22 in precursor B cell^^',^; cytoplasmic CD3 in precursor T cells2*; and CD19 on precursor B cells. However, CD19 may be found on some M4 and M5 AMLS,'~ and each of the other markers mentioned above persists in the mature cell stages of their respective lineages. In contrast, VpreB gene expression ceases in mature B-cell stages. Thus, the lineage-and differentiation-stage-restricted expression of the VpreB gene makes it an especially useful marker for analysis of malignancies of progenitor B cells.
Our findings suggest that VpreB RNA expression can be a more reliable marker for early B-cell malignancies than Abbreviations are as in Table 1 antigen receptor gene rearrangement. Neither T-cell receptor gene (TCR) nor immunoglobulin gene (Ig) rearrangement have proved to be faithful markers of lineage commitment in the acute leukemias. TCR rearrangements in precursor B-ALLs are common. TCRy, -a, -p, and -6 rearrangements have been found in some 55%, 80%, 61%, and 33% of cases, r e s p e c t i~e l y .~~-~ In AML, TCR rearrangements were also detected, but at a lower frequency." IgH rearrangements occur in about 10% to 15% of T-ALLs~~,~' and in about 20% of AML case^.^'.^^ Although Ig light chain gene rearrangement is more restricted to the B-cell lineage, it occurs at a relatively late stage of B-cell differentiation and would not be universally useful in analysis of precursor B-cell malignancies.
Two of our observations suggest that VpreB RNA is expressed very early in B-cell development. Previous studies have shown that CML B-cell blast crises have begun rearrangement of the Ig heavy chain genes while the chronic phase and myeloid blast crises of CML retain germline heavy chain gene^.'^.^' In the present study, CML B-progenitor cell blast crises expressed the VpreB gene while myeloid blast crises did not. This finding suggests that VpreB gene expression occurs during B-cell differentiation as early as, if not earlier than, the first rearrangements of the Ig heavy chain and indicates that VpreB gene expression may be one of the earliest events in B-cell development. The finding that leukemic cells from one of three patients with AUL expressed the VpreB gene also suggests that this gene is activated at a very early stage of B lymphopoiesis. AUL cells can have Ig or TCR genes in germline configuration or show rearrangements of both TCR and Ig genes; however, they are thought to represent fairly early cells in terms of lymphoid-lineage commitment.'* Our results suggest that VpreB gene expression may identify an AUL subtype that has undergone commitment to the B-cell lineage. AUL prognosis varies somewhat among the currently recognized subtype~.~' Thus, it will be important to examine a large number of AUL samples to determine if VpreB RNA expression coincides with the definition of one of the AUL subtypes or if VpreB gene expression correlates with prognosis or response to treatment.
Our control experiments showed that 1 pg of total RNA from p r e -h e l l line Nalm 16 contained sufficient VpreB RNA to be detectable by our Northern blot assay (Fig 2) . We do not expect that the level of sensitivity in our Northern blot screening of p r e -h e l l leukemias would be greatly different because we have not seen large differences in the level of VpreB RNA expressed among human or mouse p r e -h e l l lines' (our unpublished observations). Therefore, we anticipate that Northern blot analysis of VpreB expression could be used to identify most precursor B-cell malignancies. For malignancies such as AUL, which in some cases may be in the earliest stages of B-cell development, the levels of VpreB RNA expression could be lower and, therefore, could be missed by Northern blot analysis. In these cases a more sensitive technique, such as polymerase chain reaction (PCR), may be useful, although care would be necessary to ensure that normal pre-B cells would not contaminate samples and give rise to falsepositive signals.
The very close correlation of VpreB RNA expression with the leukemias of precursor B-cell phenotype suggests that the VpreB gene is specifically expressed only in leukemias that arise from cells that were commited to the B-cell lineage of differentiation. However, as more samples are analyzed, exceptions to this generalization may well be encountered.
If we assume that the malignancies we have studied represent normal stages of differentiation, our results suggest that VpreB RNA is first expressed very early in B-lineage differentiation and is restricted to early stages of cells in the B-cell lineage because VpreB RNA expression is downregulated at the stage in which B cells express surface Ig. Thus, this study supports our earlier suggestions' that the VpreB gene could be useful as a marker for analysis of precursor B-cell malignancies and as a tool for studies of early B-cell differentiation. For personal use only. on November 11, 2017 . by guest www.bloodjournal.org From
